Literature DB >> 10613938

Predictors of adverse events with intramuscular ketamine sedation in children.

S M Green1, N Kuppermann, S G Rothrock, C B Hummel, M Ho.   

Abstract

STUDY
OBJECTIVE: Ketamine is a safe and effective sedative for emergency department procedures in children. However, the use of ketamine sometimes is associated with airway complications, emesis, and recovery agitation. We wished to identify predictors of these adverse events that clinicians might use to risk-stratify children who are candidates for ketamine sedation.
METHODS: We analyzed data from 1,021 ED intramuscular ketamine sedations in children 15 years of age or younger at a university medical center and an affiliated county hospital over a 9-year period. Five potential predictor variables (age, gender, American Society of Anesthesiologists' [ASA] risk classification, quantity of first ketamine dose, and number of ketamine doses administered) were compared between children with and without complications. We used multiple logistic regression analyses to determine the association of these 5 variables with emesis and recovery agitation, and validated these analyses with bootstrap resampling techniques. We compared children with and without airway complications using univariate statistics alone, as there were too few patients with airway complications to support a multivariate analysis.
RESULTS: No study variables had significant univariate associations with airway complications (all P values >.40). We found emesis to be associated with increasing age in multivariate analysis (odds ratio [OR] 1.25 per year, bias-corrected 95% confidence interval [CI] 1.17 to 1.34, P<.001). The incidence of emesis was 12. 1% in children aged 5 years or older, and 3.5% in those younger than 5 years (Delta8.6%, 95% CI 4.9% to 12.1%). Recovery agitation was associated with the presence of an underlying medical condition (ie, ASA class > or =2, OR 3.05, bias-corrected 95% CI 1.65 to 7.30, P=.004) and inversely associated with increasing age (OR 0.79 per year, bias-corrected 95% CI 0.69 to 0.89, P<.001). The incidence of recovery agitation was 17.9% in ASA class 1 children and 33.3% in children in ASA class 2 or greater (Delta-15.4%, 95% CI 0.0% to -30. 7%). The incidence of recovery agitation was 12.1% in children aged 5 years or older, and 22.5% in those younger than 5 years (Delta-10. 4%, 95% CI -3.0% to -17.7%). Bootstrap resampling techniques validated the importance of the significant variables identified in the regression analyses.
CONCLUSION: No study variable was predictive of ketamine-associated airway complications. Emesis that occurred after ketamine administration was modestly associated with increasing age. Recovery agitation was modestly associated with decreasing age and the presence of an underlying medical condition. The discriminatory power of these variables was low enough as to be unlikely to alter clinical decisions regarding patient selection for ketamine administration. No evidence of a significant ketamine dose relationship was noted for airway complications, emesis, or recovery agitation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613938     DOI: 10.1016/s0196-0644(00)70102-8

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  16 in total

1.  Comparison of ketamine and ketofol for deep sedation and analgesia in children undergoing laser procedure.

Authors:  Marija Stevic; Nina Ristic; Ivana Budic; Nebojsa Ladjevic; Branislav Trifunovic; Ivan Rakic; Marko Majstorovic; Ivana Burazor; Dusica Simic
Journal:  Lasers Med Sci       Date:  2017-07-12       Impact factor: 3.161

2.  Propofol and propofol-ketamine in pediatric patients undergoing cardiac catheterization.

Authors:  A Akin; A Esmaoglu; G Guler; R Demircioglu; N Narin; A Boyaci
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

Review 3.  Pharmacological management of pain and anxiety during emergency procedures in children.

Authors:  R M Kennedy; J D Luhmann
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Use of midazolam and ketamine as sedation for children undergoing minor operative procedures.

Authors:  D K L Cheuk; W H S Wong; E Ma; T L Lee; S Y Ha; Y L Lau; G C F Chan
Journal:  Support Care Cancer       Date:  2005-04-22       Impact factor: 3.603

5.  Pediatric Procedural Sedation Using the Combination of Ketamine and Propofol Outside of the Emergency Department: A Report From the Pediatric Sedation Research Consortium.

Authors:  Jocelyn R Grunwell; Curtis Travers; Anne G Stormorken; Patricia D Scherrer; Corrie E Chumpitazi; Jana A Stockwell; Mark G Roback; Joseph Cravero; Pradip P Kamat
Journal:  Pediatr Crit Care Med       Date:  2017-08       Impact factor: 3.624

6.  Predictors of emesis in children undergoing procedural sedation with intramuscular ketamine in a paediatric emergency department.

Authors:  Shruthi Suryaprakash; Lai Peng Tham
Journal:  Singapore Med J       Date:  2016-12-09       Impact factor: 1.858

Review 7.  Ketamine for paediatric sedation/analgesia in the emergency department.

Authors:  M C Howes
Journal:  Emerg Med J       Date:  2004-05       Impact factor: 2.740

8.  The Lancaster experience of 2.0 to 2.5 mg/kg intramuscular ketamine for paediatric sedation: 501 cases and analysis.

Authors:  R G McGlone; M C Howes; M Joshi
Journal:  Emerg Med J       Date:  2004-05       Impact factor: 2.740

9.  Procedural Sedation Outside of the Operating Room Using Ketamine in 22,645 Children: A Report From the Pediatric Sedation Research Consortium.

Authors:  Jocelyn R Grunwell; Curtis Travers; Courtney E McCracken; Patricia D Scherrer; Anne G Stormorken; Corrie E Chumpitazi; Mark G Roback; Jana A Stockwell; Pradip P Kamat
Journal:  Pediatr Crit Care Med       Date:  2016-12       Impact factor: 3.624

10.  Is atropine needed with ketamine sedation? A prospective, randomised, double blind study.

Authors:  P Heinz; G C Geelhoed; C Wee; E M Pascoe
Journal:  Emerg Med J       Date:  2006-03       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.